Navigation Links
Data evaluates rehospitalization and cost burden of AFib/atrial flutter
Date:5/4/2011

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation (AFib), the most common form of cardiac arrhythmia. Each study evaluates these costs and updates a growing body of evidence suggesting that the true costs of AFib are complex and may not yet be fully understood. The patient populations studied mimic those in the landmark ATHENA trial, a placebo-controlled, double-blind, parallel arm trial to assess the safety and efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.

Dronedarone is an antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AFib) or atrial flutter (AFL), with a recent episode of AFib/AFL and associated cardiovascular risk factors (i.e., age >70, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter ≥50 mm or left ventricular ejection fraction [LVEF] <40%), who are in sinus rhythm or who will be cardioverted.

Editorial support for development of this poster was funded by sanofi-aventis U.S. Inc.

Lead investigator, Alpesh N. Amin, MD, University of California, Irvine, is available to discuss key findings following each session.

WHERE: HeartRhythm 2011
San Francisco, CA or via Teleconference

WHEN: Thursday, May 5th, 9:00 AM PT
"Cost Burden to U.S. Payors of ATHENA-Like Patients with Atrial Fibrillation/Atrial Flutter" (poster presentation 11-A-5161-HRS)

Thursday, May 5th, 2:00 PM PT
"Rehospitalization Rates and Costs in Hospitalized ATHENA-Like U.S. Patients with Atrial Fibrillation/Atrial Flutter" (oral presentation 11-A-5148-HRS)

Atrial Fibrillation is the most common form of cardiac arrhythmia. It is associated with an increased risk for stroke , heart failure and death and its prevalence is expected to rise as the population ages In fact, as a growing population of Americans begins to reach their Medicare years, AFib which disproportionately affects those over the age of 65 has the potential to be a largely unrecognized cost-driver.


'/>"/>

Contact: Tom Murphy
tmurphy@ccapr.com
202-609-6005
Chandler Chicco Agency
Source:Eurekalert

Related medicine news :

1. Study evaluates costs and benefits of new chemotherapy drugs
2. Study evaluates costs and benefits associated with new colon cancer therapies
3. Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment
4. Burden of HIV/TB infections increasingly falling on Hispanic community
5. Late-stage melanoma results in economic burden
6. NJHA: Charity Care Must Be a Priority as Uninsured Burden Grows
7. Inequities exists in disease burden, health care and access for minority children
8. For Migraine Sufferers, Stigma Adds to Burden
9. International liver cancer congress provides possible solutions to reduce significant burden
10. Kroll Fraud Solutions' New HITECH Hotline Eases Burden of Data Breach Notification for Healthcare
11. Insurance Woes Can Add to Burden of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
Breaking Medicine Technology: